PharmaEssentia Announces Phase II Results of P1101, an Innovative, Mono-pegylated Interferon in Patients with Chronic HCV Genotype 2 Infection

TAIPEI, Feb. 22, 2016 /PRNewswire/ -- PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 2 infection at the 25^th Conference of the Asian Pacific Association for the Study of the Liver, taking place in Tokyo, Japan from February 20 to 24, 2016 (APASL 2016). Data will be presented by the study coordinating investigator Prof. Wan-Long Chuang (Taiwan) at the HCV parallel oral session on Feb 23^rd (08:50-10:10).

"We are pleased to have the study results released at this landmark medical event," stated Ko-Chung Lin, PhD, founder & managing director of PharmaEssentia Corp. He also added: "We believe that collected data constitute a solid basis for the concept of substantial improvement of the product safety profile while maintaining antiviral efficacy, and support transition into the phase III, targeting the high unmet medical need in genotype 2 HCV, especially in Asian countries".

Prof. Chuang mentioned that "P1101 has fewer adverse events than peginterferon alfa-2a. The antiviral efficacy of biweekly P1101 at 360 mcg plus daily oral ribavirin is comparable to that of weekly peginterferon alfa-2a at 180 mcg plus daily oral ribavirin. Administration of the drug every two weeks may lead to the substantial improvement with potential to translate into higher compliance and better long term treatment outcomes."

About the drug

Ropeginterferon alfa-2b (P1101) is a novel, investigational, long-acting mono-pegylated recombinant proline-interferon alfa-2b with a 40kD branched polyethylene glycol chain conjugated predominantly at its N-terminus. P1101 is being developed for hepatitis C, hepatitis B and myeloproliferative neoplasms. P1101 is a designated Orphan Drug to treat Polycythemia Vera in USA and EU.

About PharmaEssentia Corporation

PharmaEssentia Corporation is a clinical stage biopharmaceutical company, headquartered in Taipei, Taiwan. Since the foundation in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading biotechnology and pharmaceutical companies in the US, its main goal is to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases. P1101 is one of several innovative drugs from the company's development pipeline.

For more information contact:

Shu-Fen Li
Phone Number: +886-2-2655-7688
Email: [email protected]

SOURCE PharmaEssentia